ONE LEVEL DEEPER
GILD
Warren Buffett frameworkThe Owner-OperatorBenjamin Graham frameworkThe Value ArchitectMichael Mauboussin frameworkThe Expectations EngineerHoward Marks frameworkThe Cycle WhispererPeter Lynch frameworkThe Everyday Edge

A 1.43% earnings yield can't justify equity risk when treasuries yield 4.33% and inventory days triple.

cautiousLeaning Bearishconviction

This framework sees a company priced for heroic growth at 17.5x earnings despite fundamental deterioration in working capital efficiency and extreme HIV concentration risk.

THE LENSES
THE MARGIN OF SAFETYvulnerable

Does the price protect me from permanent loss of capital?

Trading at 17.46x earnings vs DCF fair value of $165.27, implying 15.5% discount
Market pricing implies 26% perpetual growth vs actual 2.4% trailing growth
P/E at 73rd percentile of 10-year range despite operational challenges
EV/EBITDA at 72.64x, in 93rd percentile historically

The framework finds no margin of safety at current levels. While the DCF suggests modest undervaluation, the market's implied 26% growth rate against 2.4% actual growth reveals pricing based on fantasy, not fundamentals. At the 73rd percentile of historical P/E range, the price offers no protection from disappointment.

P/E Ratio
EARNINGS YIELD VS BONDSunfavorable

Does equity risk justify the premium over risk-free returns?

Earnings yield of 1.43% vs treasury yield of 4.33%
Negative 290 basis point spread to risk-free rate
2.4% revenue growth insufficient to close yield gap
Free cash flow yield of 2.05% also below treasuries

This framework finds the risk-reward unfavorable. A 1.43% earnings yield against 4.33% treasuries means accepting -290bp penalty for equity risk. With only 2.4% growth, the earnings yield cannot mathematically exceed treasury rates for decades.

Earnings Yield
THE EARNINGS RECORDmixed

Has management demonstrated consistent earnings over many years?

82.1% positive earnings surprises over 39 quarters
Operating margin recovered from -64.6% in Q1'24 to 37.4% in Q4'25
26 double beats vs 7 double misses in tracking period
Revenue growth decelerated to 2.4% TTM from higher historical rates

The framework sees a mixed record. While the company beats estimates reliably, the massive Q1'24 loss and decelerating growth trajectory raise concerns about earnings quality. The recovery proves resilience but also reveals vulnerability to one-time charges.

Operating Income
BALANCE SHEET FORTRESSadequate

Can this business survive prolonged adversity?

Current ratio of 1.68, highest in company history
Debt-to-equity at 1.09, 0th percentile historically
Interest coverage of 11.2x in Q4'25
Days inventory outstanding exploded to 376.9 from 102.4 in Q3'25

This framework finds fortress-like balance sheet metrics undermined by operational deterioration. While liquidity and leverage ratios appear strong, the 268% spike in inventory days signals working capital stress that traditional balance sheet metrics miss.

Current Ratio
KEY NUMBERS
VERDICT

Applying this framework reveals a troubling disconnect between price and fundamentals. The 1.43% earnings yield demands growth that operational metrics contradict — inventory days tripling while the market prices 26% perpetual expansion. The balance sheet appears strong until you examine working capital efficiency. Most concerning: institutions accumulate while insiders flee. Does Mr. Market see opportunity where management sees risk?

This analysis applies Benjamin Graham's published investment framework to publicly available financial data. It is not authored by, endorsed by, or affiliated with Benjamin Graham. Educational purposes only. Not financial advice.

OTHER PERSPECTIVES
Warren Buffett framework
The Owner-Operator
Leaning Bullish
Michael Mauboussin framework
The Expectations Engineer
Leaning Bearish
Peter Lynch framework
The Everyday Edge
Leaning Bearish
Howard Marks framework
The Cycle Whisperer
Bearish
Explore
Comcast CorporationCMCSAPaychex, Inc.PAYXConstellation Energy CorporationCEGPalantir Technologies Inc.PLTRCrowdStrike Holdings, Inc.CRWDVertex Pharmaceuticals IncorporatedVRTX
EDUCATIONAL ONLY · NOT FINANCIAL ADVICEv2